Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
9.33
-0.96 (-9.33%)
At close: Oct 23, 2026, 4:00 PM EDT
9.30
-0.03 (-0.32%)
Pre-market: Oct 26, 2026, 7:03 AM EDT
Sutro Biopharma Employees
Sutro Biopharma had 128 employees as of June 30, 2026. The number of employees decreased by 116 or 47.54% compared to the same quarter last year. That makes Sutro Biopharma the 29,933rd largest employer in the world and 3,822nd in the United States.
Employees
128
Change (1Y)
-116
Growth (1Y)
-47.54%
Revenue / Employee
$357,047
Profits / Employee
-$1,411,219
Market Cap
154.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 128 | -116 | -47.54% |
| Mar 31, 2026 | 133 | -136 | -50.56% |
| Dec 31, 2025 | 137 | -173 | -55.81% |
| Sep 30, 2025 | 178 | -128 | -41.83% |
| Jun 30, 2025 | 244 | -60 | -19.74% |
| Mar 31, 2025 | 269 | -31 | -10.33% |
| Dec 31, 2024 | 310 | 8 | 2.65% |
| Sep 30, 2024 | 306 | 8 | 2.68% |
| Jun 30, 2024 | 304 | 7 | 2.36% |
| Mar 31, 2024 | 300 | 8 | 2.74% |
| Dec 31, 2023 | 302 | 24 | 8.63% |
| Sep 30, 2023 | 298 | 39 | 15.06% |
| Jun 30, 2023 | 297 | 55 | 22.73% |
| Mar 31, 2023 | 292 | 58 | 24.79% |
| Dec 31, 2022 | 278 | 54 | 24.11% |
| Sep 30, 2022 | 259 | 41 | 18.81% |
| Jun 30, 2022 | 242 | 38 | 18.63% |
| Mar 31, 2022 | 234 | 39 | 20.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Coherus Oncology | 144 |
| Molecular Partners AG | 134 |
| Adagene | 128 |
| MediWound | 121 |
| Upstream Bio | 75 |
| Sionna Therapeutics | 59 |
| ALX Oncology Holdings | 48 |
STRO News
- 4 days ago - Sutro Biopharma doses first patient in STRO-006 trial - TheFly
- 4 days ago - Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors - GlobeNewsWire
- 26 days ago - Sutro Biopharma appoints Donigian as SVP, Business Development - TheFly
- 26 days ago - Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development - GlobeNewsWire
- 5 weeks ago - Sutro Biopharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Sutro Biopharma reports Q2 EPS ($2.33), consensus ($2.27) - TheFly
- 2 months ago - H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data - TheFly
- 2 months ago - Sutro Biopharma price target lowered to $34 from $41 at Citizens - TheFly